Catalent, the Somerset-based provider of drug delivery technologies, is continuing its growth in Europe, acquiring a new facility in Gosselies, Belgium, it announced this week.
The company said in a news release that it has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA, and its 32,400-square-foot facility, which will be used to accommodate Catalent’s new commercial-scale plasmid DNA manufacturing.
The facility, which has an existing clean room and other laboratory and warehouse space, will be reequipped for Catalent’s needs. It is located on Catalent’s existing campus in Gosselies and represents the third acquisition at the location.
“The Center of Excellence we have established in Belgium brings critical experience and expertise together on one campus, allowing for key synergies to best support our customers,” Manja Boerman, president of Catalent Cell & Gene Therapy, said in a prepared statement.